• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oncotelic Therapeutcs Inc (OP:OTLC)

    0.0364 -0.0007 (-1.89%)
    Streaming Delayed Price Updated: 2:49 PM EDT, Apr 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Oncotelic Therapeutcs Inc

    < Previous 1 2 3 4 Next >
    AINewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in AINewsWire Editorial on AI-Driven Pharma Compliance
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research
    Via Investor Brand Network
    AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
    Via Investor Brand Network
    Topics Artificial Intelligence
    TechMediaBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Enters Robotics And AI Biopharma Partnership With Oncotelic Therapeutics (OTCQB: OTLC)
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
    From AINewsWire
    Via GlobeNewswire
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026
    Via Investor Brand Network
    Topics Artificial Intelligence Regulatory Compliance
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
    Via Investor Brand Network
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Growth Stocks: NGTF, AMLM, CSDX, OTLC, ECGI Across Robotics, Precious Metals, MedTech and Blockchain
    Via AB Newswire
    Topics Economy Intellectual Property
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
    From NetworkNewsWire
    Via GlobeNewswire
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Key IP Portfolio Advancements Align with Biotech Asset Trend
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
    From BioMedWire
    Via GlobeNewswire
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
    From Oncotelic Therapeutics, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Oncotelic Therapeutics Inc.’s (OTLC) Deciparticle(TM) Platform Expands Possibilities in Immunology and Oncology
    Via Investor Brand Network
    Topics Intellectual Property
    InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus
    Via Investor Brand Network
    Topics Intellectual Property
    Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline
    Via Investor Brand Network
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform
    Via Investor Brand Network
    Topics Artificial Intelligence Regulatory Compliance
    Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology
    Via Investor Brand Network
    NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences
    Via Investor Brand Network
    Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
    Via Investor Brand Network
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.